Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An inflammatory disease involving a pathogenic inflammatory response in the muscle tissue.
Biomarker and diagnostic research for myositis disease has been reported in the published literature.
21 clinical trials registered, 9 recruiting. Interventions under study include other interventions, drug therapy, biologic therapy, and medical devices. Pipeline includes 1 PHASE4, 2 PHASE3, 5 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06587724](https://clinicaltrials.gov/study/NCT06587724) |
Data assembled from 3 of 12 sources · Last updated Sep 17, 2026, 7:20 PM UTC
Investigation of the Validity, Reliability, and Responsiveness of the BETY-BQ in Myositis |
— |
Hacettepe University |
RECRUITING |
[NCT06925542](https://clinicaltrials.gov/study/NCT06925542) | A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease | PHASE1 | CRISPR Therapeutics | RECRUITING |
[NCT05895786](https://clinicaltrials.gov/study/NCT05895786) | A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)] | PHASE3 | Pfizer | RECRUITING |
[NCT06991114](https://clinicaltrials.gov/study/NCT06991114) | AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. | PHASE2 | Artiva Biotherapeutics, Inc. | RECRUITING |
[NCT05251415](https://clinicaltrials.gov/study/NCT05251415) | Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases | — | University Hospital, Toulouse | RECRUITING |
241 publications have been identified in PubMed for myositis disease. Research spans Basic Science / Preclinical (51%), Review / Meta-Analysis (27%), and Epidemiology / Natural History (10%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 122 | 51% |
Research summaries | 66 | 27% |
Disease patterns and progression | 24 | 10% |
Testing and diagnosis research | 9 | 4% |
Clinical study results | 8 | 3% |
New treatment approaches | 6 | 2% |
Patient case studies | 5 | 2% |
Other research | 1 | 0% |
Salamt N (2026). [PMID: 42216994](https://pubmed.ncbi.nlm.nih.gov/42216994/). *Mol Biol Rep*. [Review / Meta-Analysis]
Pongtarakulpanit N (2026). [PMID: 41678167](https://pubmed.ncbi.nlm.nih.gov/41678167/). *Clin Exp Rheumatol*. [Diagnostic / Biomarker]
Fritz R (2026). [PMID: 41829907](https://pubmed.ncbi.nlm.nih.gov/41829907/). *Nutrients*. [Basic Science / Preclinical]
Kondo Y (2026). [PMID: 41544243](https://pubmed.ncbi.nlm.nih.gov/41544243/). *Cardiovasc Res*. [Basic Science / Preclinical]
Pryce BR (2026). [PMID: 41419070](https://pubmed.ncbi.nlm.nih.gov/41419070/). *Biochimica et biophysica acta. Molecular basis of disease*. [Basic Science / Preclinical]
Kozdrowicki M (2026). [PMID: 41758637](https://pubmed.ncbi.nlm.nih.gov/41758637/). *Cardiovasc Res*. [Basic Science / Preclinical]
Viana DPDC (2026). [PMID: 41828544](https://pubmed.ncbi.nlm.nih.gov/41828544/). *International journal of molecular sciences*. [Basic Science / Preclinical]
Shi C (2026). [PMID: 41239549](https://pubmed.ncbi.nlm.nih.gov/41239549/). *Aging cell*. [Basic Science / Preclinical]
Murphy A (2026). [PMID: 41364196](https://pubmed.ncbi.nlm.nih.gov/41364196/). *J Neuropathol Exp Neurol*. [Basic Science / Preclinical]
Langston PK (2026). [PMID: 41775886](https://pubmed.ncbi.nlm.nih.gov/41775886/). *Nat Immunol*. [Basic Science / Preclinical]
AI-curated news mentioning myositis disease
Updated Jun 6, 2026
A case report details a rare overlap syndrome of pembrolizumab-induced myocarditis, myositis, and myasthenia gravis in a patient with endometrial carcinoma. The report highlights concurrent hepatitis and thyroiditis, emphasizing the complexity of immune-related adverse events.
A recent study highlights the complexities of diagnosing and treating calcinosis cutis and delayed-onset myositis in a patient with suspected localized scleroderma. This case underscores the need for careful evaluation in rare disease presentations.